# Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

> **NCT05098704** · PHASE2,PHASE3 · RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 90 (estimated)

## Conditions studied

- Scleroderma
- Systemic Sclerosis

## Interventions

- **DRUG:** clopidogrel treatment
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05098704
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-22
- **Primary completion:** 2031-06
- **Final completion:** 2031-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098704, "Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05098704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*